Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

1 Wimpole Street, London, United Kingdom

Genesis 2025: Maximising Returns from Life Science Innovation

This high-impact life sciences conference provides a unique platform for insightful discussions, deal-making, and strategic networking—all designed to accelerate the translation of cutting-edge science into [...]

Go to Top